Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

New hepatitis B vaccine offers superior protection for people with HIV

A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Two distinct types of fatty liver disease identified

Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease - a liver-specific type and a systemic type that affects other organs and tissues.

10 Dec 2024

Two new subtypes of MASH revealed with different risks and outcomes

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population.

9 Dec 2024

New vaccine approach shows promise against Hepatitis C

Globally, approximately 58 million people are chronically infected with HCV, resulting in 290,000 annual deaths due to complications such as liver cirrhosis and liver cancer.

6 Dec 2024

Telemedicine and peer support show promise in treating hepatitis C in rural areas

New research reveals a dramatic improvement in diagnosing and curing people living with hepatitis C in rural communities using both telemedicine and support from peers with lived experience in drug use.

27 Nov 2024

Study shows cancers are uniformly growing masses

Researchers at the University of Cologne and the Centre for Genomic Regulation (CRG) in Barcelona have discovered that cancer grows uniformly throughout its mass, rather than at the outer edges.

26 Nov 2024

Mursla Bio's EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-center clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial College London, University Hospital of Santa Maria and the Medical University of Graz.

From Mursla Bio 25 Nov 2024

Mursla Bio announces promising results for EvoLiver test in liver cancer detection

25 Nov 2024

Could medical imaging innovation be the catalyst for precision medicine?

Precision medicine leverages genetic and lifestyle data to customize treatments, enhancing healthcare efficiency and patient outcomes in disease management.

24 Nov 2024

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.

15 Nov 2024

Leveraging genetic variations for more effective cancer therapies

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups.

14 Nov 2024

UAB researchers reverse liver disease in mice with gene therapy

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than 40 million people.

13 Nov 2024

HMGB1 as a key mediator in liver disease pathogenesis

Liver diseases, both acute and chronic, continue to pose significant clinical challenges due to high morbidity and mortality rates.

8 Nov 2024

Exploring the protective effects of HSD17B13 in hepatic steatosis

Chronic liver disease (CLD) is a growing global health challenge, accounting for millions of deaths each year. Its major contributors include metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), and hepatitis C virus infection.

8 Nov 2024

Exploring the anticancer potential of medicinal plants

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, environmental, and genetic factors.

8 Nov 2024

Targeting ferroptosis for overcoming chemoresistance in digestive tract tumors

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant tumors worldwide.

8 Nov 2024

New study reveals how tumor cells evade the immune system

It is comparatively easy to tell a cell's state of health: On their surface, cells present fragments of almost all the proteins they contain inside.

6 Nov 2024

NCCN leaders collaborate to enhance cancer care in Vietnam

As part of ongoing work to define and advance high-quality cancer care globally, leaders from the National Comprehensive Cancer Network (NCCN) - an alliance of leading cancer centers in the United States - will be in Vietnam today to collaborate on improving cancer care standards throughout the country.

1 Nov 2024